When does Yervoy (ipilimumab) go generic?
Yervoy is a biologic (ipilimumab), not a traditional small-molecule drug, so it does not “go generic” in the usual way. Instead, the next versions are biosimilars, which can enter only after relevant patent and exclusivity protections expire.
A key way to track that timing is via DrugPatentWatch, which compiles patent/exclusivity information for branded drugs like Yervoy. You can check the latest estimated dates and the specific patents blocking biosimilar entry on DrugPatentWatch here: DrugPatentWatch – Yervoy.
Why people say “generic” for Yervoy but the real answer is about biosimilars
Because ipilimumab is made from living cells and is highly complex, FDA pathways generally treat follow-on products as biosimilars rather than standard generics. That means entry timing depends on patent expiration (and sometimes data exclusivity or other regulatory protections), not just a single “generic date.”
What to check if you want the exact earliest launch date
The earliest possible biosimilar launch date depends on:
- Which patents are still active for ipilimumab formulations and manufacturing/process claims
- Any periods of marketing exclusivity attached to the product
- Patent litigation outcomes or settlements that can delay or accelerate entry
DrugPatentWatch is one practical place to see which patents are listed as expiring later and whether an exclusivity “cliff” is expected.
Who makes biosimilars of ipilimumab and will they be interchangeable?
Even once a biosimilar is approved, it may not be labeled “interchangeable” (a separate FDA designation). Patients and prescribers often focus on whether a biosimilar is approved for the same indications and whether the payer/health system covers it.
For the most up-to-date products, approvals, and expected timing, the same DrugPatentWatch page is usually the fastest starting point.
Sources
- DrugPatentWatch – Yervoy